XML 58 R47.htm IDEA: XBRL DOCUMENT v3.25.3
DERIVATIVE FINANCIAL INSTRUMENTS - Gain (Loss) on Derivative Financial Instruments (Details) - USD ($)
$ in Millions
3 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Gain (loss) on derivative financial instruments    
Amount of Gain (Loss) Recognized in OCI on Derivatives $ 31 $ (111)
Amount of Gain Reclassified from AOCI into (Loss) Earnings 0 10
Cash flow hedges    
Gain (loss) on derivative financial instruments    
Amount of Gain (Loss) Recognized in OCI on Derivatives 16 (47)
Amount of Gain Reclassified from AOCI into (Loss) Earnings 0 10
Net investment hedges    
Gain (loss) on derivative financial instruments    
Amount of Gain (Loss) Recognized in OCI on Derivatives 15 (64)
Amount of Gain Reclassified from AOCI into (Loss) Earnings 0 0
Foreign currency forward contracts | Cash flow hedges    
Gain (loss) on derivative financial instruments    
Amount of Gain (Loss) Recognized in OCI on Derivatives 16 (47)
Foreign currency forward contracts | Net investment hedges    
Gain (loss) on derivative financial instruments    
Amount of Gain (Loss) Recognized in OCI on Derivatives 0 (64)
Amount of Gain Reclassified from AOCI into (Loss) Earnings 0 0
Foreign currency forward contracts | Net investment hedges | Derivatives Designated as Hedging Instruments:    
Gain (loss) on derivative financial instruments    
Gain recognized in earnings related to the amount excluded from effectiveness testing 3 7
Foreign currency forward contracts | Net sales | Cash flow hedges    
Gain (loss) on derivative financial instruments    
Amount of Gain Reclassified from AOCI into (Loss) Earnings 0 10
Cross-currency swap contracts | Net investment hedges    
Gain (loss) on derivative financial instruments    
Amount of Gain (Loss) Recognized in OCI on Derivatives 15 0
Amount of Gain Reclassified from AOCI into (Loss) Earnings 0 $ 0
Cross-currency swap contracts | Net investment hedges | Derivatives Designated as Hedging Instruments:    
Gain (loss) on derivative financial instruments    
Gain recognized in earnings related to the amount excluded from effectiveness testing $ 3